DiscGenics gets go-ahead for clinical study for degenerative disc disease

Written by Alan Condon | October 28, 2019 | Print  |

Biopharmaceutical company DiscGenics is enrolling 24 patients in a clinical study for the treatment of degenerative disc disease, reports HJ News.

The trial will study the efficacy of IDCT — an allogenic, injectable disc cell therapy — in treating mild to moderate degenerative disc disease. 

An independent data safety monitoring company gave the all-clear after it completed a final mid-trial safety review following the treatment of the first six subjects in the high dose study group.

DiscGenics plans to treat a total of 60 subjects in the clinical study.

More articles on biologics:
Dr. Erich Anderer discusses the impact of a single payer system in spine
Differences in Canadian, U.S. spine care: Q&A with Dr. Stephanie de Vere
Dr. Thomas Loftus: How a single-payer system would harm spine practice in the US

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers